Lifeloc Technologies, Inc
Lifeloc Technologies designs and sells portable and fixed-station breath alcohol testing instruments, with a core franchise in evidential breathalyzers for law enforcement, workplace testing, and corrections. The company is also building a second growth leg in drug-detection technologies, including the SpinDetect/SpinDx product pipeline, while supporting customers with calibration systems, supplies, training, and services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePortable hand-held and fixed-station breathalyzers used for evidential and screening applications.
Automatic calibration tools and related hardware that keep testing programs compliant and operational.
Mouthpieces, accessories, and other recurring items used with breath-testing devices.
Instructor-led and online training through Lifeloc University and related education assets.
Emerging product development for centrifugal drug-analysis and near/remote sensing solutions.
Products
Reported · share of revenue- Product Sales and Supplies90.6 %
- Training Certification and Data Recording7.6 %
- Service Plans and Equipment Rental1.0 %
- Royalties0.4 %
- Rental Income0.4 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Lifeloc sells to law enforcement agencies, corrections facilities, workplace safety programs, and OEM customers that need reliable alcohol testing equipment. It also serves distributors and direct end users globally, with demand tied to regulated testing, safety-sensitive workplaces, and compliance-driven screening programs.
Buys evidential breathalyzers such as the FC Series for roadside and criminal enforcement use.
Buys DOT-approved devices and calibration tools for federally regulated and safety-sensitive workplaces.
Buys portable and fixed testing systems for inmate and facility screening programs.
Buy components or subsystems, including ignition interlock-related parts and other testing hardware.
Buy inventory for local market distribution and to extend Lifeloc's geographic reach.
Strategy
Lifeloc is trying to broaden beyond alcohol breath testing into drug-detection technologies while continuing to support its installed base with training, calibration, and consumables. Management is also expanding direct sales and distributor coverage, which is intended to widen market access and improve repeat business from regulated customers.
A new product line could diversify revenue beyond breath alcohol testing and support a return to growth.
Broader market coverage should increase account wins and improve penetration in domestic and international markets.
Training, calibration, and service offerings make the installed base more sticky and support recurring revenue.
Geography
Lifeloc is headquartered in Wheat Ridge, Colorado and sells in the U.S. and internationally through direct sales and distributors. The company does not provide a country revenue table in the excerpts, but management explicitly says it is expanding domestic and international distribution and expects sales growth in the U.S. and worldwide.
Risks
The business is exposed to lumpy order patterns, especially for OEM and ignition-interlock-related components, and demand can swing with enforcement intensity and workplace testing activity. Lifeloc is also still investing in new products while operating losses continue, so execution risk around commercialization, distribution expansion, and cost control remains important.
Many orders are placed on an intermittent purchase-order basis, so revenue may not recur at a steady rate.
Exposure: OEM and ignition interlock components
The company is spending on development and demonstrations before the new platform is proven in the market.
Exposure: Drug-detection product pipeline
Management says losses have continued in 2025 and may continue until new products gain traction.
Exposure: Company-wide profitability
Products must remain approved, accurate, and competitively priced in regulated testing markets.
Exposure: Law enforcement and workplace testing
Raw materials, labor, and freight inflation can reduce gross margin if not passed through.
Exposure: Manufacturing and distribution
Accounting
Judgemental itemsDemand can be uneven, so excess or obsolete inventory risk can affect cost of sales and working capital.
Impact: Gross margin and current assets
Future tax benefit recognition depends on expected profitability, which is uncertain while losses continue.
Impact: Balance sheet and tax expense
Testing devices may require post-sale support and returns estimates that change with product mix and usage.
Impact: Revenue, liabilities, and margins
The STS acquisition created intangible assets whose amortization affects operating profit.
Impact: Operating expenses and asset values
Headquarters and production assets are depreciated over estimated useful lives, affecting earnings timing.
Impact: Operating income
Similar listed companies
Publicly listed companies with a comparable business focus.
Cyberloq Technologies, Inc.
CLOQ · Services-Prepackaged Software
Interlink Electronics, Inc
LINK · Computer Peripheral Equipment, NEC
Interlink Electronics designs and manufactures sensors, printed electronics, and human-machine interface components used in custom and standard products.
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Standard BioTools Inc
LAB · Pharmaceutical Preparations
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Last updated: 24/09/2026